Rabeprazole-d4 is intended for use as an internal standard for the quantification of rabeprazole by GC- or LC-MS. Rabeprazole is a proton pump inhibitor that selectively and irreversibly inhibits the gastric H+/K+ ATPase (IC50 = 72 nM).1 It can be activated more rapidly and over a greater pH range than other proton pump inhibitors such as omeprazole , lansoprazole , and pantoprazole .2 Rabeprazole (30 mg/kg) inhibits gastric acid secretion in pylorus-ligated rats and a rat model of gastric fistula.3 It also inhibits the growth of several strains of H. pylori in vitro (MIC50s = 1.57-3.13 μg/mL).2 Formulations containing rabeprazole have been used in the treatment of ulcers, pathological hypersecretory conditions, and gastroesophageal reflux disease (GERD).
1.Morii, M., Takata, H., Fujisaki, H., et al.The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+,K+-ATPase is correlated with the rate of acid-activation of the inhibitorBiochemical Pharmacology39(4)661-667(1990) 2.Williams, M.P., and Pounder, R.E.Review article: The pharmacology of rabeprazoleAlimentary Pharmacology and Therapeutics13(3)3-10(1999) 3.Tomiyama, Y., Morii, M., and Takeguchi, N.Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differentlyBiochem. Pharmacol.48(11)2049-2055(1994)